QURE – uniqure n.v. - ordinary shares (US:NASDAQ)
Stock Stats
News
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
uniQure (NASDAQ: QURE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
uniQure (NASDAQ: QURE) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $10.00 to $9.00. They now have a "neutral" rating on the stock.
uniQure (NASDAQ: QURE) had its price target lowered by analysts at Royal Bank of Canada from $16.00 to $14.00. They now have an "outperform" rating on the stock.
uniQure (NASDAQ: QURE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $28.00 price target on the stock.
Form 8-K uniQure N.V. For: Nov 21
Form SCHEDULE 13G/A uniQure N.V. Filed by: Nantahala Capital Management, LLC
Form SC 13G/A uniQure N.V. Filed by: Vestal Point Capital, LP
Form SC 13G/A uniQure N.V. Filed by: BRISTOL MYERS SQUIBB CO
Form 10-Q uniQure N.V. For: Sep 30
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.